Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments-Reference-Cited by-同舟云学术

Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments

Published:2021-11 Issue:11 Volume:14 Page:101201
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Suzuki Hiroyuki,Iwamoto Hideki,Nakano Masahito,Nakamura Toru,Masuda Atsutaka,Sakaue Takahiko,Tanaka Toshimitsu,Nakano Dan,Kuromatsu Ryoko,Niizeki Takashi,Okamura Shusuke,Shimose Shigeo,Shirono Tomotake,Noda Yu,Kamachi Naoki,Yano Hirohisa,Kawaguchi Atsushi,Koga Hironori,Torimura Takuji

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference41 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J. Clin.,2021

2. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis;El-Serag;Gastroenterology,2007

3. Hepatocellular carcinoma: From diagnosis to treatment;Grandhi;Surg. Oncol.,2016

4. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma;J. Hepatol.,2018

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma;Cell Communication and Signaling;2023-11-27

2. Comparative Oncology: Management of Hepatic Neoplasia in Humans and Dogs;Veterinary Sciences;2022-09-08

3. Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma;Computational and Structural Biotechnology Journal;2022

4. Metronomic chemotherapy and antiangiogenic drugs: Preclinical and clinical data;Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy;2022